Axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy

Condition

Cancer

Blood and Immune System

17 February 2025

Published on 13 Sep 2024
Last Updated on 17 Feb 2025

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended axicabtagene ciloleucel for inclusion on the MOH Cell, Tissue and Gene Therapy Product (CTGTP) List for treating patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. The decision was based on the unacceptable pricing proposal by the company.

Axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy (Published 13 Sep 2024) [PDF, 217 KB]

PES Chimeric antigen receptor T-cell therapies for relapsed or refractory large B-cell-lymphoma (updated 17 Feb 2025) [PDF, 106 KB]